Princeton Portfolio Strategies Group LLC lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,930 shares of the pharmaceutical company’s stock after selling 200 shares during the period. Princeton Portfolio Strategies Group LLC’s holdings in Vertex Pharmaceuticals were worth $249,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America raised its holdings in Vertex Pharmaceuticals by 0.6% during the 1st quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares during the period. FNY Partners Fund LP raised its holdings in Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after buying an additional 900 shares during the period. Dupont Capital Management Corp acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $186,000. Finally, State of Alaska Department of Revenue acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $197,000. Hedge funds and other institutional investors own 92.85% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up 0.50% during midday trading on Monday, hitting $155.88. The stock had a trading volume of 379,155 shares. The firm has a market capitalization of $39.30 billion, a price-to-earnings ratio of 149.74 and a beta of 1.73. The firm has a 50-day moving average price of $153.96 and a 200-day moving average price of $133.53. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.33. The business had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s revenue was up 26.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Holdings Cut by Princeton Portfolio Strategies Group LLC” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/09/vertex-pharmaceuticals-incorporated-vrtx-holdings-cut-by-princeton-portfolio-strategies-group-llc.html.

VRTX has been the topic of several recent analyst reports. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a report on Tuesday, July 4th. Needham & Company LLC upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a report on Friday, June 23rd. BidaskClub downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 28th. Finally, J P Morgan Chase & Co set a $184.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twenty-three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $167.04.

In related news, CEO Jeffrey M. Leiden sold 216,624 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $160.96, for a total transaction of $34,867,799.04. Following the transaction, the chief executive officer now directly owns 400,266 shares of the company’s stock, valued at approximately $64,426,815.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul M. Silva sold 43,443 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $161.07, for a total value of $6,997,364.01. Following the transaction, the senior vice president now directly owns 26,516 shares in the company, valued at $4,270,932.12. The disclosure for this sale can be found here. Insiders have sold a total of 518,357 shares of company stock worth $83,154,633 over the last three months. 1.80% of the stock is owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.